It is possible that a specific inhibitor of MVP in terms of its interaction with YPEL4 would allow the MAPK pathway to simultaneously work with the PI3K pathway, suggesting that a specific MVP inhibitor would serve as a therapeutic target in asthma by promoting the activity of YPEL4. This evidence concerns the gene MVP and asthma.